European Journal of Cancer
Volume 41, Issue 18 , Pages 2789-2791 , December 2005

Response to the publication: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer

  • Pere Gascón

      Affiliations

    • Hospital Clinic, ARIBAU 161, Pral. 1a, Barcelona 08036, Spain
    • Corresponding Author InformationCorresponding author. Tel./fax: +34 93 227 5402.
    • ,
  • Heinz Ludwig

      Affiliations

    • Wilhelminenspital der Stadt Wien, Montlearstrasset 37, Vienna 1160, Austria

Received 14 July 2005 ,Accepted 18 July 2005.

References 

  1. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer. 2004;40:2201–2216
  2. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood. 2002;100:2303–2320
  3. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001;19:2875–2882
  4. Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin-α increases hemoglobin and improves quality of life in anaemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer. 2003;98:1072–1079
  5. Campos S. Epoetin alfa 40000U once weekly significantly improves hemoglobin and quality of life in anaemic patients with ovarian cancer. Proc Am Soc Clin Oncol. 2003;22:774;[Abstract 3111]
  6. Crawford J, Robert F, Perry M, Belani CP, Sarokhan B, for the Anaemia Prevention in NSCLC Study Group . Epoetin alfa 40000U once weekly maintains hemoglobin in advanced non-small cell lung cancer patients receiving first-line chemotherapy. Proc Am Soc Clin Oncol. 2003;22:628;[Abstract 2527]
  7. Hudis C, Williams D, Gralow JR, the PROCRIT Study Group . Epoetin alfa maintains hemoglobin and quality of life in breast cancer patients receiving conventional adjuvant chemotherapy: final report. Proc Am Soc Clin Oncol. 2003;22:767;[Abstract 3084]
  8. Rushing DA, Einhorn LH, Wildgust M, for the PROCRIT Study Group . Epoetin alfa 40000U once weekly significantly improves hemoglobin and quality of life in anaemic colorectal cancer patients. Proc Am Soc Clin Oncol. 2003;22:771;[Abstract 3098]
  9. Straus DJ, Testa MA, Riggs SA, et al. Early treatment with epoetin alfa improves anaemia, quality of life (QOL), and productivity in patients (Pts) with hematologic malignancies and mild anaemia during chemotherapy (CT). Blood. 2003;102:497a;[Abstract 1811]
  10. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomised, double-blind study of epoetin alfa compared with placebo in anaemic patients receiving chemotherapy. J Clin Oncol. 2005;23:2606–2617
  11. Chang J, Couture F, Young S, et al. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol. 2005;23:2597–2605
  12. NCCN. National Comprehensive Cancer Network (NCCN): Clinical practice guidelines in oncology: cancer and treatment-related anaemia. Available from: http://www.nccn.org/physician_gls/f_guidelines.html, 2005.
  13. Durie BG, Kyle RA, Belch A, et al. Myeloma management guidelines: a consensus report from the scientific advisors of the International Myeloma Foundation. Hematol J. 2003;4:379–398
  14. Ludwig H. Supportive therapies in the management of myeloma. Oncology (Huntingt). 2004;18:295–296298
  15. EPREX®/ERYPO® [summary of product characteristics]. JJPRD, Great Britain, UK, Ortho Biotech, a division of Janssen-Cilag, 2004.
  16. PROCRIT® [package insert]. Raritan, NJ, Ortho Biotech Products, L.P., May, 2004.

PII: S0959-8049(05)00785-9

doi: 10.1016/j.ejca.2005.07.021

European Journal of Cancer
Volume 41, Issue 18 , Pages 2789-2791 , December 2005

Article Tools